Navigation Links
'Rare' cancers in the spotlight at major European conference
Date:2/24/2010

More should be done across Europe to ensure that people with rare forms of cancer are not denied access to the best possible treatment, say the organizers of a major European cancer conference to be held in Milan on 9 and 10 March 2010.

"People with rare diseases have the same right to receive proper treatment as all other patients", said Dr. Paolo G. Casali, Head of the Sarcoma Medical Treatment Unit at the Milan Istituto Nazionale Tumori and co-chair of the ESMO Conference on Sarcoma and GIST. "Yet the sad reality is that access to treatments for rare cancers varies across Europe. And patients with these tumors do not always receive the best possible care."

"Focusing on these forms of cancer can have wider benefits," Dr. Casali added. "Many rare cancers are exceptionally rich of targets for the new molecularly targeted therapies. Sarcomas are an obvious case: they are relatively rare, they can be split into 50-plus subgroups, they have plenty of targets, they are serving as an advanced model for medical oncologists. This Conference highlights all this."

The ESMO Conference on Sarcoma and GIST is part of the European Society for Medical Oncology's strong commitment to cover the newest therapies and address issues related to rare cancers. The conference will present the latest developments in the diagnosis and treatment of a group of rare cancers that affect the body's connective tissues.

Known as soft tissue sarcomas, these tumors can be found in muscle, blood vessels, deep skin tissues, nerves and the tissues around joints. GIST, or gastrointestinal stromal tumour, is a type of sarcoma that originates from the wall of the gastrointestinal tract. Around 50 different kinds of soft-tissue sarcomas have been identified. Altogether, connective tissue cancers affect about 25,000 people in Europe each year.

"Therapies in sarcomas present many real challenges," said Dr.Paolo Dei Tos Director of the Pathology Unit of the
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Scientists fear rare dolphin driven to extinction by human activities
2. Student study bolsters case for adding a rare sunflower to the endangered species list
3. Rare albino ratfish has eerie, silvery sheen
4. Student study bolsters case for adding a rare sunflower to the endangered species list
5. Rare cancer-causing syndrome found, for the first time, in Singapore
6. New, rare and threatened species discovered in Ghana
7. Threatened birds may be rarer than geographic range maps suggest
8. Scat sniffing dogs detecting rare California carnivores
9. Bacterium sequenced makes rare form of chlorophyll
10. Researchers decode genetics of rare photosynthetic bacteria
11. Researchers decode genetics of rare photosynthetic bacterium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... PLEASANTON, Calif. , July 9, 2015 /PRNewswire/ ... tools, today announcing its acquisition of Avid Nano. ... dynamic light scattering (DLS) systems.    ... world,s smallest, fastest and easiest to use protein ... system that measures a protein,s hydrodynamic size, size ...
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... , July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... the growing mobile commerce market announces a revised version of one ... The commercial will air on CNBC in New York ... and San Francisco metro areas. ... focuses on Wocket,s ability to replace all the cards in your ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... Troy, N.Y. A team of researchers from Rensselaer ... space this week, to investigate new ways of preventing ... bacteria, that could pose a threat to the health ... Collins, assistant professor in the Department of Chemical and ...
... Ill. --- How do children reason about the natural ... and non-human animals? For decades, the consensus was ... world, they adopt an "anthropocentric" stance, favoring humans over ... of animals. But Northwestern University researchers have ...
... by controlling the behaviours of the bacteria, or by using ... These will be possible once the researchers in ... behaviours of microbial communities. The aim is to reduce the ... produce clean water and to treat wastewater. Jointly set ...
Cached Biology News:Rensselaer researchers to send bacteria into orbit aboard space shuttle Atlantis 2Animals talk, sing and act like humans? 2NTU and UNSW open joint center to study microorganisms for water and environment technologies 2NTU and UNSW open joint center to study microorganisms for water and environment technologies 3
(Date:7/29/2015)... ... July 29, 2015 , ... Available in select spas ... Bi-Gel, a nighttime-specific product that targets fat cells for extreme contouring action. During ... enter fat cells, inhibiting the formation of new fat. Upon waking CHRONODIET breaks ...
(Date:7/28/2015)... -- A n ew ... developing and commercialising innovative medicines to transform patient quality of ... experienced management team; blue chip ... BioPharma Group Ltd ("Mereo"), a recently-formed speciality biopharmaceutical company, announces ... gross, from blue chip institutional investors and simultaneously acquired a ...
(Date:7/28/2015)... Seahorse Bioscience, the industry leader in ... of XF Technology which is increasingly being adopted ... the links between mitochondrial function and disease are ... rapidly.   Recently, 12 peer-reviewed publications ... (NPG) featuring XF Technology, including Nature, Nature Genetics, ...
(Date:7/28/2015)... 2015 Deerfield Management Company, L.P. today announced ... which will invest in groundbreaking advancements in science that ... and orphan diseases. The venture capital fund will also ... developed and improve the way healthcare is delivered to ... healthcare-focused venture funds in the sector, will donate all ...
Breaking Biology Technology:Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3
... ... efficient. With the most available leg-room, energy efficient impellers, and new service-friendly control panel, ... ... The all-new Allergard 619 Animal Transfer Station (ATS) from NuAire is ergonomic, portable, and ...
... ... and a “fascinatingly weird” ancient culture. , ... (PRWEB) June 11, 2010 -- U.S. nonprofit The OTS Foundation has devised ... megalithic architects in Frequently Asked Question format. With content drawn from a handbook in ...
... , ... more prevalent in clinical research, key issues around open source technology are highlighted at leading ... Washington, DC ... year’s annual meeting of the Drug Information Association (DIA). The DIA Annual Meeting ...
Cached Biology Technology:The Allergard 619: an All-new Animal Transfer Station from NuAire 2New tool for exploring the ancient world. 2Open Source Clinical Trials Software Featured at the 46th DIA Annual Meeting 2Open Source Clinical Trials Software Featured at the 46th DIA Annual Meeting 3
... The TOPO Cloning Kits for Sequencing allow ... The kits contain TOPO Cloning vectors with primer ... from the PCR product insertion site. This minimizes ... be read before reaching the sequence of your ...
Zebrafish Vitellogenin ELISA System, 96 wells. ELISARange: 0.5-100 ng/ml.Sensitivity: 0.3 ng/ml.Sample volume: 100 ul.Suitable for use with Zebrafish plasma samples.3-h protocol.Store at 2-8 C. Categ...
... 1;heading 2;Many mammalian ... experimental situations create ... transfection and other ... ViraPower Lentiviral Expression ...
...
Biology Products: